Centralized Filings To Increase Under European Pharmaceutical Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislation mandates that AIDS, cancer, diabetes and neurodegenerative products be centrally filed through EMEA. Roughly 100% of applications filed in Europe are expected to go through the centralized process when the legislation goes into effect in November, according to EMEA Executive Director Thomas Löngrenn.
You may also be interested in...
FDA, EMEA To Hold Joint Scientific Advice Meetings With Sponsors
One-year pilot program will launch in January to address specific development issues for breakthrough products. Meetings will provide an "opportunity to optimize product development" and are expected to help avoid unnecessary replication or divergence in agency methodologies, FDA and EMEA say.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.